Karyopharm Therapeutics
KPTI
KPTI
77 hedge funds and large institutions have $316M invested in Karyopharm Therapeutics in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
77
Holders Change
+4
Holders Change %
+5.48%
% of All Funds
1.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
37
Reduced
14
Closed
4
Calls
$1.3M
Puts
$123K
Net Calls
+$1.18M
Net Calls Change
+$751K
Top Buyers
| 1 |
JPMorgan Chase & Co
New York
|
+$2.95M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.47M |
| 3 |
Millennium Management
New York
|
+$1.67M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.63M |
| 5 |
IHM
Iguana Healthcare Management
New York
|
+$1.1M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.48M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$823K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$452K |
| 4 |
Barclays
London,
United Kingdom
|
-$325K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$222K |
